Effects of aspirin consumption during pregnancy on pregnancy outcomes: Meta‐analysis
- 1 February 2003
- journal article
- research article
- Published by Wiley in Birth Defects Research Part B: Developmental and Reproductive Toxicology
- Vol. 68 (1) , 70-84
- https://doi.org/10.1002/bdrb.10002
Abstract
BACKGROUND: We assessed the effects and safety of aspirin treatment during pregnancy on fetal and neonatal outcomes. METHODS: We searched MEDLINE (1966–2001), EMBASE (1980–2000), TOXLINE (1994–2000), EBM Cochrane Database of Systematic Reviews (1991–2000), Reproductive Toxicology (2001), teratology texts, and bibliographies of all the included studies. We looked for published randomized controlled studies reporting aspirin treatment to improve outcomes of moderate‐ and high‐risk pregnancies. The key words used to search for articles about exposure to aspirin were salicylic acid, pregnancy, and pregnancy complications; key words used to search for outcome were neonatal diseases and abnormalities. Based on our search strategy, 1904 citations were identified; their titles and abstracts were reviewed by one reviewer. Of these citations, 182 papers were selected for detailed review. Two reviewers independently determined whether a study should be included in the final analysis. In cases of disagreement, the decision was based on the assessment of a third reviewer. RESULTS: Data were extracted independently by each reviewer. We calculated the pooled relative risk (RR) or weighted mean difference and 95% confidence intervals (CI), assuming a random‐effect model. Thirty‐eight studies met the inclusion criteria. The risk for miscarriage did not differ between women treated with aspirin and placebo (seven studies; RR, 0.92; 95% CI, 0.71–119). Women who took aspirin had a significantly lower risk of preterm delivery than did those treated with placebo (22 studies; RR, 0.92; 95% CI, 0.86–0.98). There was no significant difference in perinatal mortality (20 studies; RR, 0.92; 95% CI, 0.81–1.05) and in the rate of small‐for‐gestational‐age infants (12 studies; RR, 0.96; 95% CI, 0.87–1.07) among offspring of mothers treated with aspirin and those of mothers treated with a placebo. CONCLUSION: For women with moderate‐ and high‐risk pregnancies, aspirin treatment seemed to have a small but significant effect on reducing the rate of preterm deliveries, but did not reduce the rate of perinatal death. Birth Defects Research (Part B) 68:70–84, 2003.Keywords
This publication has 37 references indexed in Scilit:
- Time-Dependent Effects of Low-Dose Aspirin Administration on Blood Pressure in Pregnant WomenHypertension, 1997
- Do low-risk pregnant women with antiphospholipid antibodies need to be treated?American Journal of Obstetrics and Gynecology, 1997
- Low-Dose Aspirin in High-Risk Pregnancy?Hypertension in Pregnancy, 1997
- Neonatal outcome in a randomized, controlled trial of low‐dose aspirin in high‐risk pregnanciesJournal of Paediatrics and Child Health, 1995
- The effect of low-dose aspirin on pregnancies complicated by elevated human chorionic gonadotropin levelsAmerican Journal of Obstetrics and Gynecology, 1995
- Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertensionThe Lancet, 1993
- Low-dose Aspirin in Prophylaxe und Therapie des SchwangerschaftshochdrucksGynäkologisch-geburtshilfliche Rundschau, 1992
- Low-Dose Aspirin Does Not Influence the Clinical Course of Women With Mild Pregnancy-Induced HypertensionObstetrics & Gynecology, 1990
- Effect of Low-Dose Aspirin on Fetal and Maternal Generation of Thromboxane by Platelets in Women at Risk for Ppregnancy-Induced HypertensionNew England Journal of Medicine, 1989
- The Use of Aspirin to Prevent Ppregnancy-Induced Hypertension and Lower the Ratio of Thromboxane A2to Prostcyclin in Relatively High Risk PregnanciesNew England Journal of Medicine, 1989